Literature DB >> 2242528

Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features.

E Deutsch1, M Berger, W G Kussmaul, J W Hirshfeld, H C Herrmann, W K Laskey.   

Abstract

The clinical, electrocardiographic, and coronary hemodynamic responses to sequential 90-second occlusions of the left anterior descending coronary artery in 12 patients undergoing elective percutaneous transluminal coronary angioplasty were examined. Transmyocardial lactate metabolism was examined in an additional group of seven patients with clinical and hemodynamic features similar to the first group. We noted that in comparison with the initial balloon occlusion the second occlusion was characterized by less subjective anginal discomfort, less ST segment shift (0.44 +/- 0.13 versus 0.21 +/- 0.07 mV, p = 0.01), and lower mean pulmonary artery pressure (25 +/- 1.0 versus 20 +/- 1.7 mm Hg, p = 0.005). In addition, for the same heart rate-blood pressure product, cardiac vein flow during the second inflation was significantly lower than that recorded during the first inflation (96 +/- 1.4 versus 83 +/- 2.4 ml/min, p = 0.005). Finally, there was significantly less myocardial lactate production during the second inflation (lactate extraction ratio: first inflation, -0.11 +/- 0.03; second inflation, -0.03 +/- 0.02; p = 0.04). We conclude that the lessened clinical, electrocardiographic, hemodynamic, and metabolic evidence of myocardial ischemia during the second of two periods of coronary artery occlusion during percutaneous transluminal coronary angioplasty supports the concept of adaptation to myocardial ischemia (ischemic preconditioning).

Entities:  

Mesh:

Year:  1990        PMID: 2242528     DOI: 10.1161/01.cir.82.6.2044

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  72 in total

Review 1.  Myocardial preconditioning: basic concepts and potential mechanisms.

Authors:  S Okubo; L Xi; N L Bernardo; K Yoshida; R C Kukreja
Journal:  Mol Cell Biochem       Date:  1999-06       Impact factor: 3.396

Review 2.  Apoptosis in myocardial ischaemia and infarction.

Authors:  P A J Krijnen; R Nijmeijer; C J L M Meijer; C A Visser; C E Hack; H W M Niessen
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

Review 3.  Signaling and cellular mechanisms in cardiac protection by ischemic and pharmacological preconditioning.

Authors:  Michael Zaugg; Marcus C Schaub
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

4.  Stress proteins, self defence, and the myocardium.

Authors:  S A Thorne; V R Winrow; D R Blake
Journal:  Br Heart J       Date:  1992-04

Review 5.  The electrocardiogram in ST elevation acute myocardial infarction: correlation with coronary anatomy and prognosis.

Authors:  Y Birnbaum; B J Drew
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

6.  Ischaemic preconditioning and myocardial adaptation to serial intracoronary balloon inflation: cut from the same cloth?

Authors:  M E Faircloth; S R Redwood; M S Marber
Journal:  Heart       Date:  2004-04       Impact factor: 5.994

Review 7.  Management of hyperglycemia in hospitalized patients.

Authors:  Dawn Smiley; Guillermo E Umpierrez
Journal:  Ann N Y Acad Sci       Date:  2010-10-29       Impact factor: 5.691

8.  An electrocardiographic sign of ischemic preconditioning.

Authors:  Loek P B Meijs; Loriano Galeotti; Esther P Pueyo; Daniel Romero; Robert B Jennings; Michael Ringborn; Stafford G Warren; Galen S Wagner; David G Strauss
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-04-28       Impact factor: 4.733

9.  Alpha 1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5'-nucleotidase activity.

Authors:  M Kitakaze; M Hori; T Morioka; T Minamino; S Takashima; H Sato; Y Shinozaki; M Chujo; H Mori; M Inoue
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

10.  Antiischemic effects of nicorandil during coronary angioplasty in humans.

Authors:  S Saito; T Mizumura; T Takayama; J Honye; T Fukui; T Kamata; M Moriuchi; K Hibiya; Y Tamura; Y Ozawa
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.